Arcturus Therapeutics is losing its second executive in as many weeks—Pad Chivukula, the RNA biotech’s chief scientific officer and chief operating officer, is stepping down.
Chivukula will take an advisory role with Arcturus, which headlined its announcement with the appointment of Christine Esau, previously its senior director of translational research, to the top R&D post at the company.
“It has been a privilege to be a part of the Arcturus team, and I am proud of our extraordinary innovations and accomplishments in advancing our diverse pipeline of RNA therapeutics and the many partnerships we have garnered thus far, Chivukula said in the statement. “I look forward to following the Company’s ongoing success as Arcturus continues to progress its preclinical programs.”
The news comes shortly after Arcturus’ board voted to oust then-President and CEO Joseph Payne, who was replaced in the interim with Mark Herbert, the company’s VP of business development and alliance management.
Payne didn’t go down without a fight. He had his attorneys pen a letter to Arcturus, claiming that the board of directors excluded both him and Chivukula from “board discussions and votes,” which is how he, as CEO and a board member, missed the memo that he was getting fired.
The letter laid the blame on a group of four directors—Stuart Collinson, executive chairman of the board, Craig Willett, Daniel Geffken and Intercept CMO David Shapiro—who made the decision in violation of Israeli Companies Law and then “had our client physically removed from the building.”
It also demanded Payne be reinstated in his old job, but Arcturus countered, saying he was terminated because his conduct was “contrary to the best interests of the Company and its shareholders” and that Payne had “demonstrated that he is unable to put the needs of the company and its shareholders ahead of his own self-interest.”
Arcturus backed its way onto the Nasdaq in September, through a reverse merger with Israel-based Alcobra, which, the letter alleged, is the root of “the poor corporate governance demonstrated in recent months,” that led to his ouster.
By Amirah Al Idrus
Source: Fierce Biotech
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
